Global Life Science Business Partnering (GLSBP) - September 2024

Highlights of Deals in September 2024

1.      Aurobindo to acquire 49 percent stake in GLS Pharma.

2.      Natco Pharma acquires 40 million shares in eGenesis Inc.

3.      Alkem inks licensing pact with Takeda to introduce Vonoprazan in India.

4.      Samsung Medison completes acquisition of Sonio SAS which was co-founded by Indian startup entrepreneur Deepak Prakash.

5.      Bharat Biotech collaborates with Alopexx to develop and commercialize Broad-Spectrum Anti-Microbial Vaccine.

6.      Lupin signs patent licence pact with Takeda for novel gastrointestinal drug.

7.      Lupin inks distribution pact with Celnova Pharma for 2 South American countries.

8.      Organon to buy skin therapy developer Dermavant for up to $1.2 billion.

9.      Abacus and Mirum Pharmaceuticals sign partnership agreement.

10.  Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs.

11.  Gavi inks purchase agreement for 500,000 Mpox vaccine doses from Bavarian Nordic.

12.  Korro Bio inks cardiometabolics deal with Novo Nordisk.

13.  NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs.

 

Aagami Updates:

  1. New Client Win: A Japan based CDMO specializing in Contract manufacturing of Oligonucleotide & Peptide APIs, Process and analytical development, and providing DDS solutions. Aagami will support their US expansion.
  2. Contract Extension: Awarded to Aagami by Biosimilar Client. Companies looking for Biosimilars in Japan, Asia or Elsewhere, please contact us.
  3. Aagami CEO Dinesh Jain is all set for a business trip to Japan and Korea with over 30 meetings lined up with decision makers.
  4. Bio- Europe (Nov 4-6) partnering system has opened up for meeting. Please send us your meeting requests soon.
  5. Meet us in:

          a.      Tokyo Oct 7-8 Or during BIO Japan | October 9-11, 2024| Pacifico Yokohama

          b.      And in Republic of Korea | October 14-16 | Seoul

          c.       Also in  BIO EUROPE | November 4–6, 2024 | Stockholm, Sweden  

INFOCUS: Select opportunities available:

For Partnering/Licensing/ Co-development:

  1. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses. Also MPOX. 
  2. Licensing: Several Biosimilars available for Partnering in multiple regions like Japan.                                         a.      Denosumab (Prolia® & Xgeva®)

  3. b.      Romiplostim (Nplate®) [ For immune thrombocytopenia (ITP) ]

    c.       Teriparatide (Forteo®/Forsteo®) [ For Osteoporosis ]

    d.      Liraglutide (Victoza®) [ For Diabetes ]

    e.      Tocilizumab (Actemra®) [ For Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), Active Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) and patients with coronavirus disease 2019 (COVID-19) receiving systemic corticosteroids and requiring supplemental oxygen or mechanical ventilation.

  4. Aagami CEO Dinesh Jain is all set for a business trip to Japan and Korea with over 30 meetings lined up with decision makers. 
  5. Bio Europe (Nov 4-6) partnering system has opened up for meeting. Please send us your meeting requests soon.


For Acquisition:

  1. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns. 
  2. IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).
  3. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU).

Seeking Investment:

  1. Seeking Investment: Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications.
  2. Seeking US$3 million: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity.
  3. Seeking US$4 million: Integrated Autoimmune company - Engineering Therapeutics to Block Pathogenic Autoantibodies

Hope you found the content useful. We welcome your feedback and queries. 

×
Twitter